AbbVie Inc. Long-Term Investments

Long-Term Investments of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments growth rates and interactive chart. An accounting item that represents the company's investments, including stocks, bonds, real estate, and cash. Long-term investments are assets that a company intends to hold for more than a year. The long-term investment account differs largely from the short-term investment account in that short-term investments will most likely be sold, whereas the long-term investments will not be sold for years and, in some cases, may never be sold.

Highlights and Quick Summary

  • Long-Term Investments for the quarter ending December 30, 2019 was $93 Million (a -29.01% decrease compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments decreased by -93.7%
  • Annual Long-Term Investments for 2019 was $93 Million (a -93.45% decrease from previous year)
  • Annual Long-Term Investments for 2018 was $1.42 Billion (a -32.06% decrease from previous year)
  • Annual Long-Term Investments for 2017 was $2.09 Billion (a 17.22% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments of AbbVie Inc.

Most recent Long-Term Investmentsof ABBV including historical data for past 10 years.

Interactive Chart of Long-Term Investments of AbbVie Inc.

AbbVie Inc. Long-Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $93.0 $131.0 $1,473.0 $1,477.0 $93.0
2018 $1,420.0 $1,463.0 $1,505.0 $2,057.0 $1,420.0
2017 $2,090.0 $1,971.0 $2,052.0 $2,123.0 $2,090.0
2016 $1,783.0 $1,378.0 $1,400.0 $387.0 $1,783.0
2015 $145.0 $74.0 $134.0 $93.0 $145.0
2014 $92.0 $124.0 $130.0 $119.0 $92.0
2013 $118.0 $123.0 $121.0 $118.0 $118.0
2012 $119.0 $202.62 $237.0 $221.47 $119.0
2011 $229.0 $229.0
2010 $137.36 $137.36

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.